However, despite a 16.4% reduction in total daily insulin following drug initiation to mitigate hypoglycemia risk (Cherney, Perkins, Soleymanlou, Maione, et al., 2014; Perkins et al., 2014), such adjustments are a standard part of care for individuals with T1D who are also receiving other antidiabetic treatments. The gene discussed is INS; the disease is type 1 diabetes mellitus.